Free Trial

Ono Pharmaceutical (OTCMKTS:OPHLF) Shares Cross Below Fifty Day Moving Average - Here's What Happened

Ono Pharmaceutical logo with Medical background

Ono Pharmaceutical Co., Ltd. (OTCMKTS:OPHLF - Get Free Report)'s stock price crossed below its 50 day moving average during trading on Monday . The stock has a 50 day moving average of $11.29 and traded as low as $10.73. Ono Pharmaceutical shares last traded at $10.73, with a volume of 5,566 shares trading hands.

Ono Pharmaceutical Stock Performance

The company has a debt-to-equity ratio of 0.14, a quick ratio of 2.80 and a current ratio of 3.55. The company's 50 day moving average is $11.29 and its 200 day moving average is $10.81. The firm has a market cap of $5.04 billion, a P/E ratio of 10.32 and a beta of 0.57.

About Ono Pharmaceutical

(Get Free Report)

Ono Pharmaceutical Co, Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers Opdivo Intravenous Infusion and Kyprolis Intravenous Injection for malignant tumors; Emend capsules/Proemend intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; and Mektovi, Velexbru, and Braftovi capsules for malignant tumors, as well as ADLUMIZ tablets for cancer cachexia.

Recommended Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Ono Pharmaceutical Right Now?

Before you consider Ono Pharmaceutical, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ono Pharmaceutical wasn't on the list.

While Ono Pharmaceutical currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 AI ETFs for Steady Gains in 2025 (Without the Wild Volatility)
Goldman Sachs Warns of 20% Market Drop—Are They Right?
Top 3 Insider Stock Buys in April—Are They Still Good in May?

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines